Employees: 03 (2023.0)Legal category: Société à responsabilité limitée (sans autre indication)Size: PMECreation date: 2015-08-11 (10 years)Status: ActiveBusiness sector: Commerce de détail de produits pharmaceutiques en magasin spécialiséLocation: FLOING (08200), Ardennes
Les données financières de cette entreprise sont partiellement disponibles (liasse simplifiée ou données confidentielles). Certaines sections ne sont pas affichées.
EURL PHARMACIE MARGUERITTE : revenue, balance sheet and financial ratios
EURL PHARMACIE MARGUERITTE is a French company
founded 10 years ago,
specialized in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé.
Based in FLOING (08200),
this company of category PME
shows in 2023 a revenue of 1.8 M€.
Find below the complete financial statements, solvency ratios, working capital requirements and sector comparison.
Financial history - EURL PHARMACIE MARGUERITTE (SIREN 813046869)
Indicator
2025
2024
2023
2022
2020
2019
2018
2017
2016
Revenue
N/C
N/C
1 826 463 €
N/C
N/C
N/C
N/C
N/C
N/C
Net income
64 969 €
55 286 €
90 124 €
160 197 €
166 231 €
211 804 €
185 916 €
201 721 €
64 096 €
EBITDA
N/C
N/C
169 985 €
N/C
N/C
N/C
N/C
N/C
N/C
Net margin
N/C
N/C
4.9%
N/C
N/C
N/C
N/C
N/C
N/C
Revenue and income statement
In 2025, EURL PHARMACIE MARGUERITTE generates positive net income of 65 k€. Net income represents the final profit after all expenses (operating, financial, exceptional) and corporate tax. Change over 2016-2025: 64 k€ -> 65 k€.
Net income (2025)
?
Net income
Definition
Profit or loss after all expenses, including taxes and exceptional items.
Formula
Current income + Exceptional income - Income tax
64 969 €
Loading income statement...
Income statement
Item
Amount
% Revenue
Change
The detailed income statement is not available for this company (simplified accounts or confidential data).
Chart evolution
Show :
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Assets
Loading data...
Item
Gross
Deprec.
Net
%
Change
Assets balance sheet data not available for this company
Liabilities
Loading data...
Item
Year
%
Change
Liabilities balance sheet data not available for this company
Solvency and debt ratios
The debt ratio (= Financial debt / Equity x 100) stands at 453%. Critical situation: debt significantly exceeds equity, severely limiting borrowing capacity and exposing the company to default risk. Financial autonomy (= Equity / Total assets x 100) reaches 17%. Low autonomy: the company heavily depends on external financing (banks, suppliers).
Debt ratio (2025)
?
Debt ratio
Definition
Measures the proportion of debt to equity.
Formula
(Financial debt / Equity) x 100
Interpretation
< 50% : Low 50-100% : Moderate > 100% : High
453.368%
Financial autonomy (2025)
?
Financial autonomy
Definition
Share of equity in the company's total financing.
Formula
(Equity / Total assets) x 100
Interpretation
> 30% : Good autonomy 20-30% : Average < 20% : Low
16.784%
Asset age ratio (2025)
?
Asset age ratio
Definition
Measures the degree of wear of tangible assets.
Formula
Accumulated depreciation / Gross fixed assets x 100
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2022
2023
2024
2025
Debt ratio
2423.712
566.38
307.472
191.006
1069.292
1173.714
725.589
572.289
453.368
Financial autonomy
3.637
13.646
22.694
31.996
7.82
7.089
11.233
13.642
16.784
Repayment capacity
None
None
None
None
None
None
18.752
None
None
Cash flow / Revenue
None%
None%
None%
None%
None%
None%
5.339%
None%
None%
Sector positioning
Debt ratio
453.372025
2023
2024
2025
Q1: 13.7
Med: 49.79
Q3: 129.09
Watch
In 2025, the debt ratio of EURL PHARMACIE MARGUERITTE (453.37) ranks in the top 25% of the sector. This ratio measures the weight of debt relative to equity. A high ratio may indicate excessive dependence on external financing.
Financial autonomy
16.78%2025
2023
2024
2025
Q1: 33.42%
Med: 53.72%
Q3: 72.08%
Watch
In 2025, the financial autonomy of EURL PHARMACIE MARGUERITTE (16.8%) ranks in the bottom 25% of the sector. This ratio represents the share of equity in total financing. Low autonomy may limit investment capacity and increase vulnerability.
Repayment capacity
18.75 years2023
2023
Q1: 0.95 years
Med: 3.59 years
Q3: 7.48 years
Watch
In 2023, the repayment capacity of EURL PHARMACIE MARGUERITTE (18.75) ranks in the top 25% of the sector. This ratio indicates the number of years needed to repay debt with cash flow. A long duration may signal heavy debt relative to repayment capacity.
Liquidity ratios
The liquidity ratio (= Current assets / Current liabilities) stands at 429.71. Concretely, the company has €2 of liquid assets for every €1 of short-term debt: no cash risk within 12 months.
Liquidity ratio (2025)
?
Liquidity ratio
Definition
Ability to meet short-term debts with current assets.
Formula
Current assets / Current liabilities
Interpretation
> 1.5 : Very good 1-1.5 : Fair < 1 : Liquidity risk
Visualisation créée via abddaf.fr Sources : INPI & BCE - Retraitements : Ministère de l'économie
Indicator
2016
2017
2018
2019
2020
2022
2023
2024
2025
Liquidity ratio
206.437
236.29
303.773
376.126
333.267
340.115
439.021
388.968
429.715
Interest coverage
None
None
None
None
None
None
27.604
None
None
Sector positioning
Liquidity ratio
429.712025
2023
2024
2025
Q1: 131.03
Med: 182.25
Q3: 258.64
Excellent
In 2025, the liquidity ratio of EURL PHARMACIE MARGUERITTE (429.71) ranks in the top 25% of the sector. This ratio measures the ability to cover short-term debt with current assets. A ratio above 1 ensures comfortable coverage of short-term maturities.
Interest coverage
27.6x2023
2023
Q1: 0.38x
Med: 2.71x
Q3: 6.47x
Excellent
In 2023, the interest coverage of EURL PHARMACIE MARGUERITTE (27.6x) ranks in the top 25% of the sector. This ratio indicates how many times operating income covers interest expenses. High coverage means financial charges weigh little on profitability.
Working capital requirement (WCR) and payment terms
Working capital requirement (WCR) measures the cash timing gap between customer collections and supplier/inventory payments.
Operating WCR (2025)
?
Operating WCR
Definition
Financing requirement generated by the operating cycle (inventory + receivables - trade payables).
Formula
Inventory + Customer receivables - Trade payables
Interpretation
Negative = cash released Positive = financing needed
0 €
Customer credit (2025)
?
Customer credit (days)
Definition
Average payment term granted to customers.
Formula
(Customer receivables / Revenue incl. VAT) x 360
Interpretation
< 45j : Good 45-60j : Average > 60j : Long
0 j
Supplier credit (2025)
?
Supplier credit (days)
Definition
Average payment term obtained from suppliers.
Formula
(Trade payables / Purchases incl. VAT) x 360
Interpretation
The longer the term, the better for cash flow
0 j
Inventory turnover (2025)
?
Inventory turnover (days)
Definition
Average storage duration for goods or materials.
Formula
(Inventory / Cost of goods) x 360
Interpretation
The lower the ratio, the faster the turnover
0 j
WCR and payment terms evolution EURL PHARMACIE MARGUERITTE
Visualization created via numbers.finance Sources : INPI & BCE - Adjustments : Ministry of Economy
Indicator
2016
2017
2018
2019
2020
2022
2023
2024
2025
Operating WCR
0 €
0 €
0 €
0 €
0 €
0 €
242 299 €
0 €
0 €
Inventory turnover (days)
0
0
0
0
0
0
31
0
0
Customer payment term (days)
0
0
0
0
0
0
12
0
0
Supplier payment term (days)
0
0
0
0
0
0
33
0
0
Positioning of EURL PHARMACIE MARGUERITTE in its sector
Comparison with sector Commerce de détail de produits pharmaceutiques en magasin spécialisé
Valuation estimate
Based on 277 transactions of similar company sales
in 2025,
the value of EURL PHARMACIE MARGUERITTE is estimated at
1 032 040 €
(range 700 347€ - 1 619 413€).
This multiples method compares the actual sale price of similar companies to their financial indicators (Revenue, EBITDA, Net Income). It provides a market-based indicative estimate.
Estimated enterprise value2025
277 transactions
700k€1032k€1619k€
1 032 040 €Range: 700 347€ - 1 619 413€
NAF 5 année 2025
Valuation method used
Net Income Multiple
64 969 €
×
15.9x
=1 032 040 €
Range: 700 347€ - 1 619 413€
Only this financial indicator is available for this company.
Valuation evolution
Visualisation creee via abddaf.fr Sources : BODACC & INPI
How is this estimate calculated?
This estimate is based on the analysis of 277 actual transactions of similar company sales (same NAF code) registered with BODACC between 2016 and 2025.
EBITDA Multiple: Preferred method for profitable SMEs. EBITDA reflects the ability to generate cash.
Revenue Multiple: Used for growing companies or those with low profitability. Reflects commercial potential.
Net Income Multiple: Relevant for mature companies with stable results.
This estimate is provided for information purposes only. A precise valuation requires in-depth analysis (assets, liabilities, prospects, market...).
Similar companies (Commerce de détail de produits pharmaceutiques en magasin spécialisé)
Compare EURL PHARMACIE MARGUERITTE with other companies in the same sector:
Frequently asked questions about EURL PHARMACIE MARGUERITTE
What is the revenue of EURL PHARMACIE MARGUERITTE ?
The revenue of EURL PHARMACIE MARGUERITTE in 2023 is 1.8 M€.
Is EURL PHARMACIE MARGUERITTE profitable?
Yes, EURL PHARMACIE MARGUERITTE generated a net profit of 65 k€ in 2025.
Where is the headquarters of EURL PHARMACIE MARGUERITTE ?
The headquarters of EURL PHARMACIE MARGUERITTE is located in FLOING (08200), in the department Ardennes.
Where to find the tax return of EURL PHARMACIE MARGUERITTE ?
The tax return of EURL PHARMACIE MARGUERITTE is available on this page. Click on a year in the 'Data by year' section to view the account details (assets, liabilities, income statement). Data comes from INPI (National Institute of Industrial Property).
In which sector does EURL PHARMACIE MARGUERITTE operate?
EURL PHARMACIE MARGUERITTE operates in the sector Commerce de détail de produits pharmaceutiques en magasin spécialisé (NAF code 47.73Z). See the 'Sector positioning' section above to compare the company with its competitors.
Item evolution
Rotate your phone to landscape mode to view the chart